Ms. Wiesengrun is a partner in FBC's Litigation Department.
Ms. Wiesengrun specializes in class actions and derivative suits, and represents leading multinational and domestic companies in their defenses against class actions. She represents major clients in a wide range of industries, including technology, pharmaceutical, e-commerce, banking and energy. Due to her extensive experience in the class actions field, Ms. Wiesengrun also serves as a mediator in complex class actions disputes.
Ms. Wiesengrun also advises and represents individuals and companies in complex disputes that relate to issues of contract and corporate law, tax, real estate, and construction.
Ms. Wiesengrun represents clients before various Israeli courts, as well as in arbitration and mediation proceedings.
Ms. Wiesengrun founded and manages the firm's Senior Citizen Support and Social Facilitation Clinic, which provides pro-bono legal advice to the elderly.
Tel Aviv University, LL.M., 2006
Tel Aviv University, LL.B. (Magna Cum Laude), 2006
משרדנו (בשיתוף ארגון היועצים המשפטיים – ACC) ערך השבוע כנס בנושא תובענות ייצוגיות בו ארחנו את רו"ח אהוד רצאבי ועו"ד ליאב וינבאום, מנהל המחלקה המסחרית בפרקליטות מחוז ת״א (אזרחי). הפאנל, בו השתתפו השניים, עסק ביתרונות השימוש בבודקים מומחים בהסדרי פשרה ובשימוש בהליכי גישור...Orit Malka & Oded Revivo & Tal Wiesengrun & Yael Riemer & Noa Barhum | Nov 2018
FBC, in collaboration with US firm Morgan, Lewis & Bockius, represented Perrigo Company in the sale of its active pharmaceutical ingredients business headquartered in Israel for a purchase price of US$110 million. The transaction included the sale of all of the shar...Raz Tepper & Sharon Klein-Manbar & Anat Shavit & Shay Teken & Moran Friedman & Hilla Sachs & Tal Wiesengrun & Boaz Tavor | Aug 2017
Israeli Jurisdiction over Foreign Cartelists Recently, an Israeli District Court addressed the jurisdiction of Israeli courts over foreign companies accused of being part of a prohibited cartel that acted outside of Israel but had an impact on market prices – and ca...Gil Orion, Dr. & Tal Wiesengrun | Mar 2017